Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Cash & Equivalents (2016 - 2025)

Bioadaptives' Cash & Equivalents history spans 8 years, with the latest figure at $158445.0 for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 15.26% to $158445.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $158445.0, a 15.26% increase, with the full-year FY2025 number at $158445.0, up 15.26% from a year prior.
  • Cash & Equivalents hit $158445.0 in Q4 2025 for Bioadaptives, up from $59273.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for BDPT hit a ceiling of $210582.0 in Q2 2025 and a floor of $235.0 in Q2 2024.
  • Historically, Cash & Equivalents has averaged $65808.0 across 5 years, with a median of $50119.5 in 2022.
  • Biggest five-year swings in Cash & Equivalents: tumbled 99.41% in 2024 and later surged 89509.36% in 2025.
  • Tracing BDPT's Cash & Equivalents over 5 years: stood at $82936.0 in 2021, then plummeted by 69.37% to $25405.0 in 2022, then skyrocketed by 139.23% to $60776.0 in 2023, then soared by 126.19% to $137470.0 in 2024, then grew by 15.26% to $158445.0 in 2025.
  • Business Quant data shows Cash & Equivalents for BDPT at $158445.0 in Q4 2025, $59273.0 in Q3 2025, and $210582.0 in Q2 2025.